The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC.
 
Jun Miyakoshi
No Relationships to Disclose
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yuji Uehara
Honoraria - Chugai Pharma
 
Yuki Takeyasu
No Relationships to Disclose
 
Masayuki Shirasawa
No Relationships to Disclose
 
Jumpei Kashima
No Relationships to Disclose
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Hanako Ono
No Relationships to Disclose
 
Kouya Shiraishi
No Relationships to Disclose
 
Takashi Kohno
Consulting or Advisory Role - Lilly Japan
Speakers' Bureau - Lilly Japan; Lilly Japan
Research Funding - Chugai Pharma; Guardant Health; Konica Minolta; Sysmex
Patents, Royalties, Other Intellectual Property - Patent fee from Foundation Medicine Inc; Patent fee from Riken Genesis/Amoy Diagnostics; Patent fee from ThermoFisher Scientific
 
Shunsuke Kondo
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Mitsubishi Tanabe; Noile-Immune Biotech, Inc; Rakuten Medical Japan
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Yasushi Yatabe
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD K.K
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; MSD K.K
Research Funding - Konica Minolta; Merck; Thermo Fisher Scientific
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyowa Kirin International; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Takayasu Kurata
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Janssen; MSD Oncology (Inst); Takeda (Inst)
 
Katsuhiko Naoki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Parexel/CALYX (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Ohe
Leadership - JCOG
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; PharmaMar; PharmaMar; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)